secwatch.observer — SEC 8-K summary
======================================

Issuer:     MUSTANG BIO, INC. (MBIO)
CIK:        0001680048
Form:       8-K
Filed at:   2023-05-22T23:59:59+00:00
Accession:  0001558370-23-010276
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 1.02, 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mustang Bio sells facility to uBriGene for up to $11M, discontinues four CAR T programs, cuts 82% workforce
--------------------------------------------------------------------------------

- Sells Worcester cell processing facility to uBriGene for $6M upfront plus $5M contingent on $10M equity raise.
- Discontinues MB-102 (CD123), MB-103 (HER2), MB-104 (CS1), MB-105 (PSCA) programs; terminates City of Hope licenses.
- Workforce reduction of ~82% (inclusive of offered employees); expects $2.9M severance costs and $24M annualized savings.
- XSCID gene therapy program enrollment paused; awaiting data from modified vector trials; no safety concerns noted.
- Enters manufacturing services agreement with uBriGene; commits to at least $8M spend over two years for MB-106 and future pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680048/000155837023010276/0001558370-23-010276-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680048/000155837023010276/tmb-20230517x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-010276

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer